BC Extra | Dec 5, 2019
Financial News

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

Since market close on Tuesday, Arrowhead, Kodiak, Relmada and Revance raised a total of $718.5 million in follow-ons. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) raised $232 million after it priced an offering of 4 million shares at...
BC Extra | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
BC Extra | Apr 26, 2019
Company News

European regulatory roundup: CHMP opinions and a Portola approval

EMA's CHMP recommended a basket of approvals, including Dovato dolutegravir/lamivudine, Libtayo cemiplimab and two orphan therapies. Also Friday, the European Commission granted conditional approval to Ondexxya andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse...
BC Week In Review | Jan 18, 2019
Financial News

Mirati, Revance price follow-ons

Mirati Therapeutics Inc. (NASDAQ:MRTX) and Revance Therapeutics Inc. (NASDAQ:RVNC) have each raised $100 million in follow-ons. Mirati priced 1.6 million shares at $62 late on Jan. 16. The price is a slim discount to the...
BC Extra | Jan 17, 2019
Financial News

Mirati, Revance price follow-ons

Mirati Therapeutics Inc. (NASDAQ:MRTX) and Revance Therapeutics Inc. (NASDAQ:RVNC) have each raised $100 million in follow-ons. Mirati priced 1.6 million shares at $62 late Wednesday. The price is a slim discount to the company’s close...
BC Week In Review | Jun 14, 2018
Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the...
BC Extra | Jun 11, 2018
Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule...
BC Week In Review | May 18, 2018
Clinical News

FDA approves Aimovig as first CGRP inhibitor for migraines

FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late on May 17 to prevent migraine in adults. The drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the...
BC Extra | May 18, 2018
Company News

FDA approves Aimovig as first CGRP inhibitor for migraines

FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late Thursday to prevent migraine in adults. The drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the indication. Amgen...
BC Week In Review | May 18, 2018
Clinical News

FDA frowns on Evolus

Evolus Inc. (NASDAQ:EOLS) said FDA issued a complete response letter for a BLA for prabotulinumtoxinA (DWP-450) to treat adults with glabellar lines (frown lines between the eyebrows). Evolus shed over $90 million in market cap...
Items per page:
1 - 10 of 136